Imaging Biometrics: IQ-AI subsidiary receives US access programme approval for brain cancer treatment
IQ-AI Ltd (LSE:IQAI, OTCQB:IQAIF) subsidiary Imaging Biometrics has received approval for an Expanded Access Program (EAP) for oral gallium maltolate (GaM)...
Read full article »
CEO
David W.J. Smith
Imaging Biometrics develops a radiology AI platform that offers concept testing and clinical evaluation solutions for the healthcare industry.
Read more